Tue, July 9, 2019
Mon, July 8, 2019
Fri, July 5, 2019
Wed, July 3, 2019
Tue, July 2, 2019
Mon, July 1, 2019
Fri, June 28, 2019
Thu, June 27, 2019
Wed, June 26, 2019
Tue, June 25, 2019
Mon, June 24, 2019
Fri, June 21, 2019
Thu, June 20, 2019
Wed, June 19, 2019
Tue, June 18, 2019
Mon, June 17, 2019
Fri, June 14, 2019
Thu, June 13, 2019
Wed, June 12, 2019
Tue, June 11, 2019
Mon, June 10, 2019
Fri, June 7, 2019
Thu, June 6, 2019
Wed, June 5, 2019
Tue, June 4, 2019
Mon, June 3, 2019
Fri, May 31, 2019

Matthew Luchini Maintained (BLUE) at Buy with Decreased Target to $163 on, Jun 17th, 2019


  Copy link into your clipboard //stocks-investing.news-articles.net/content/201 .. th-decreased-target-to-163-on-jun-17th-2019.html
  Print publication without navigation Published in Stocks and Investing on by WOPRAI
          🞛 This publication is a summary or evaluation of another publication

Matthew Luchini of BMO Capital, Maintained "bluebird bio, Inc." (BLUE) at Buy with Decreased Target from $191 to $163 on, Jun 17th, 2019.

Matthew has made no other calls on BLUE in the last 4 months.



There are 2 other peers that have a rating on BLUE. Out of the 2 peers that are also analyzing BLUE, 1 agrees with Matthew's Rating of Hold. Following is the relevant analyst calls for the last 4 months


  • Michael Schmidt of "Leerink Swann" Downgraded from Buy to Hold on, Tuesday, March 5th, 2019


This is the rating of the analyst that currently disagrees with Matthew


  • Yaron Werber of "Cowen & Co." Initiated at Buy on, Tuesday, February 26th, 2019

Publication Contributing Sources